Silver Book Fact

Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.

Early Treatment Diabetic Retinopathy Study. http://www.nei.nih.gov/neitrials/static/study53.asp

Reference

Title
Early Treatment Diabetic Retinopathy Study
Authors
National Institutes of Health, National Eye Institute
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Eye Exams: Trends, 1996-2006 (in relation to screening for diabetic retinopathy)  
  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy progression by 54% in type 1 diabetes patients with minimal-to-moderate…  
  • Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.  
  • The cost-effectiveness of detection and treatment of eye disease in diabetics is $3,190 per quality adjusted life year (QALY).